MIRA (MIRA Pharmaceuticals, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MIRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Denil Nanji Shekhat | Director | A | — | — |
| 2026-06-15 | Matthew Paul Del Giudice | Director | A | — | — |
| 2026-06-15 | Matthew Pratt Whalen | Director | A | — | — |
| 2026-06-15 | Edward Clouston MacPherson | Director | A | — | — |
| 2026-04-01 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2025-10-03 | Denil Nanji Shekhat | Director | A | — | — |
| 2025-10-03 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2025-09-18 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2025-09-03 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2024-12-10 | Matthew Paul Del Giudice | Director | A | — | — |
| 2024-12-10 | Edward Clouston MacPherson | Director | A | — | — |
| 2024-12-10 | Matthew Pratt Whalen | Director | A | — | — |
| 2024-12-10 | Denil Nanji Shekhat | Director | A | — | — |
| 2024-12-10 | Michelle Yanez | Chief Financial Officer | A | — | — |
| 2024-12-10 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2024-11-27 | Erez Aminov | Chief Executive Officer | Sell | — | — |
| 2024-08-30 | Bay Shore Trust | 10%+ Owner | Sell | — | — |
| 2024-06-21 | Denil Nanji Shekhat | Director | A | — | — |
| 2024-05-30 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2024-05-22 | Erez Aminov | Chief Executive Officer | Buy | — | — |
| 2024-03-27 | Michelle Yanez | Chief Financial Officer | A | — | — |
| 2024-03-27 | Erez Aminov | Chief Executive Officer | A | — | — |
| 2024-03-27 | Edward Clouston MacPherson | Director | A | — | — |
| 2024-03-27 | Matthew Paul Del Giudice | Director | A | — | — |
| 2024-03-27 | Michael Allen Jerman | Director | A | — | — |
| 2024-03-27 | Denil Nanji Shekhat | Director | A | — | — |
| 2023-12-27 | Bay Shore Trust | 10%+ Owner | Sell | — | — |
| 2023-11-17 | Bay Shore Trust | 10%+ Owner | A | — | — |
| 2023-08-24 | Bay Shore Trust | 10%+ Owner | Buy | — | — |
| 2023-08-21 | Christos Nicholoudis | Director | A | — | — |
| 2023-08-21 | Michelle Yanez | CFO, Secretary and Treasurer | A | — | — |
| 2023-08-21 | Christopher C Chapman JR | Executive Chairman | A | — | — |
| 2023-08-21 | Erez Aminov | CEO and Director | A | — | — |
| 2023-08-04 | George Cappy | 10%+ Owner | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 3,530,156 | — |
| — | 10%+ Owner | 2,760,270 | — |
| — | 10%+ Owner | 670,000 | — |
| — | Director | 22,378 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MIRA quote page; the site-wide leaderboard is on the insider transactions hub.